Skip to content

Alpha Tau Medical

US · DRTS #3046 by market cap Listed 1970
11.76 +0.45 +3.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 12 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
27.34% +2.64pp
Institutions
93 +12
As of
2026/Q3 vs. prior period

Holder types

Public Company16.16%
Individual/Insider14.91%
Mutual Fund8.93%
Hedge Fund1.86%
Private Company0.23%
Family Office/Trust0.13%
Other57.76%

Top holders as of 2026-05-12

Oramed Pharmaceuticals Inc. 15.67% · 14.47M sh
Uzi Sofer 12.47% · 11.52M sh
Michael Avruch 1.64% · 1.52M sh
Gem Investment Advisors, LLC 1.55% · 1.43M sh
BlackRock 1.51% · 1.40M sh
UBS Asset Management 1.36% · 1.26M sh
HighTower Advisors, LLC 0.97% · 894.04K sh
Boothbay Fund Management, LLC 0.84% · 773.48K sh
Aquamarine Financial (Cayman) Ltd 0.78% · 721.50K sh
Yona Keisari 0.55% · 503.49K sh
Pier Capital, LLC 0.75% · 691.94K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

41 filings tracked · 0 buys · 16 sells

NameRoleStake
Michael Avruch Director 1.64%
Yona Keisari Chief Scientific Officer 0.55%
Raphi Levy Chief Financial Officer 0.10%
David Milch Independent Director 0.10%
Samuel Blumenfeld Independent Director 0.05%
Ruth Alon Independent Director --
Alan Adler Independent Director --
Nadav Kidron Director --
Maya Racine-Netser Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-20 Raphi Levy Chief Financial Officer Derivative Exercise and Sale -2,871 $2.98–15.00
2026-08-10 Raphi Levy Chief Financial Officer Derivative Exercise and Sale -17,730 $2.98–14.00
2026-07-05 Raphi Levy Chief Financial Officer Derivative Exercise and Sale -2,270 $2.98–14.00
2026-07-01 Raphi Levy Chief Financial Officer Derivative Exercise and Sale -17,873 $2.98–13.00
2026-06-30 Raphi Levy Chief Financial Officer Derivative Exercise and Sale -2,127 $2.98–13.02
2026-06-29 Raphi Levy Chief Financial Officer Open Market Disposition -20,000 $12.00
2026-06-24 Raphi Levy Chief Financial Officer Open Market Disposition -20,000 $11.00
2026-06-22 Raphi Levy Chief Financial Officer Open Market Disposition -17,500 $9.47–10.00
2026-06-02 Raphi Levy Chief Financial Officer Open Market Disposition -32,500 $10.76–10.90
2026-03-17 Ruth Alon Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Alan Adler Independent Director Initial Statement of Beneficial 0 --
2026-03-17 David Milch Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Samuel Blumenfeld Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Nadav Kidron Director Initial Statement of Beneficial 0 --
2026-03-17 Maya Racine-Netser Independent Director Initial Statement of Beneficial 0 --
2026-03-17 Raphi Levy Chief Financial Officer Initial Statement of Beneficial 0 --
2026-03-17 Michael Avruch Director Initial Statement of Beneficial 0 --
2026-02-24 Raphi Levy Chief Financial Officer Intent to Sell (Form 144) -10,000 $7.40
2026-01-12 Raphi Levy Chief Financial Officer Intent to Sell (Form 144) -15,000 $7.09
2026-01-08 Raphi Levy Chief Financial Officer Intent to Sell (Form 144) -25,000 $6.41

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

Alpha Tau Medical discussion 0 comments

Add a comment